Objective To study the serum expression of Adropin and type I collagen amino-terminal lengthening peptide (P1NP) in patients with psoriasis vulgaris (PV) and their clinical significance. Methods 70 patients with PV treated in our hospital from January 2019 to January 2021 were selected as PV group. According to the Psoriasis Lesion Area and Severity Scale (PASI), PV group was divided into mild to moderate group (PASI score ≤ 12 points, n=40) and severe group (PASI score＞12 points, n=30), and 40 healthy persons in the same period were selected as control group. Enzyme-linked immunosorbent assay was used to detect the serum level of Adropin, P1NP and tumor necrosis factor-α（TNF-α），interleukin (IL)-8. The correlation was conducted by Pearson correlation analysis. Multivariate logistic regression analysis was used to analyze the factors affecting the severity of PV. The ROC curve analyzes the evaluation value of each index on the severity of PV. Results The serum expression of Adropin, P1NP in PV group were significantly lower than that in the control group (t=13.828, 15.993, P＜0.05).Serum level of Adropin and P1NP in severe group were significantly lower than those in mild and moderate group, while hs-CRP, TNF-α，IL-8 were significantly higher than those in mild and moderate group (P＜0.05). The levels of Adropin, P1NP were negatively correlated with hs-CRP, TNF-α, IL-8 in patients with PV (P＜0.05). Serum Adropin and P1NP were independent protective factors that affect the occurrence of severe PV, while hs-CRP was a risk factor. The area under the curve of Adropin, P1NP, and hs-CRP combined for the diagnosis of severe PV was 0.933 (0.866~0.967), which was higher than the single indicator of 0.853 (0.806~0.899), 0.817 (0.743~0.851), and 0.848 (0.793~0.881) (Z=5.864, 5.072, 5.776, all P＜0.05).Conclusion The levels of Adropin and P1NP in peripheral blood of patients with PV are decreased, which are related to the severity of PV. The combined detection of Adropin, P1NP and hs-CRP is helpful to evaluate the severity of PV